Adverts

Open Access Articles- Top Results for JWH-193

JWH-193

</th></tr>
JWH-193
220px
Systematic (IUPAC) name
(1-(2-morpholin-4-ylethyl)indol-3-yl)-4-methylnaphthalen-1-ylmethanone
Clinical data
Identifiers
133438-58-1 7pxY
PubChem CID 10250276
ChemSpider 8425762
Chemical data
Formula C26H26N2O2
398.496 g/mol
 14pxY (what is this?)  (verify)

JWH-193 is a drug from the aminoalkylindole family which acts as a cannabinoid receptor agonist. It was invented by the pharmaceutical company Sanofi-Winthrop in the early 1990s. JWH-193 has a binding affinity at the CB1 receptor of 6nM, binding around seven times more tightly than the parent compound JWH-200,[1] though with closer to twice the potency of JWH-200 in activity tests. A structural isomer of JWH-193 with the methyl group on the indole ring instead of the naphthoyl ring, was also found to be of similarly increased potency over JWH-200.[2][3]

File:6-methyl-JWH-200.png
6-Methyl-JWH-200

See also

References

  1. ^ Huffman JW, Padgett LW. Recent Developments in the Medicinal Chemistry of Cannabimimetic Indoles, Pyrroles and Indenes. Current Medicinal Chemistry, 2005; 12: 1395-1411.
  2. ^ Eissenstat MA et al. (August 1995). "Aminoalkylindoles: structure-activity relationships of novel cannabinoid mimetics". Journal of Medicinal Chemistry 38 (16): 3094–105. PMID 7636873. doi:10.1021/jm00016a013. 
  3. ^ Shim JY et al. (November 1998). "Three-dimensional quantitative structure-activity relationship study of the cannabimimetic (aminoalkyl)indoles using comparative molecular field analysis". Journal of Medicinal Chemistry 41 (23): 4521–32. PMID 9804691. doi:10.1021/jm980305c. 


Lua error in package.lua at line 80: module 'Module:Buffer' not found.